Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by nozzpackon Aug 04, 2021 4:11pm
436 Views
Post# 33649707

Long history of Safety Concerns

Long history of Safety Concerns In May 2014, the company announced that it had completed pre-clinical studies on ATB-346.[7] 

In late June 2014, following approval from 
Health Canada, the company announced the first human dosing for Phase I of its human clinical trials.[8] 

In mid-January 2015, the company announced that clinical trials for its ATB-346 were being suspended due to safety concerns; clinical trials were restarted in March 2015.


So, what you are now seeing, after 6 more years, are the same safety concerns.

Lets face it.
This ultimate solution to GI side effects has been on the go since 2009.

Yet, its progression through clinical trials has not moved a single step.

That is a huge red flag that is now showing up in many fake clinical trials of drugs that, with clever promotion , can still take in the sheeple who know not what they buy.

GLTA

This is a failed drug that will never get approved due to significant safety concerns 
<< Previous
Bullboard Posts
Next >>